Respiratory syncytial virus and influenza activity are on the rise in parts of the country, particularly among young children, according to the CDC's latest respiratory virus updates. Overall, the ...

This year's headlines on respiratory syncytial virus (RSV) focused largely on the relatively new vaccines -- including a new ...

Public health officials reiterated the importance of vaccines after seeing a rise in circulating levels of respiratory syncytial virus (RSV).

The federal government will place RSV vaccines on the national immunisation program, as 12,000 babies are hospitalised with ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Weekly COVID-19 case numbers reported by the Montana Department of Public Health and Human Services continue to drop.There ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The Centers for Disease Control and Prevention (CDC) recently warned that respiratory syncytial virus (RSV) and mycoplasma pneumonia, or “walking pneumonia,” are on the rise among very young children.

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...